Skip to main content

Spruce Biosciences, Inc.

corporate_fare Company Profile

Spruce Biosciences, Inc.

SPRB·NASDAQ·Life Sciences·CIK 0001683553

The company is a biopharmaceutical company that develops and sells new treatments for neurological disorders where current medical options are insufficient. Founded in April 2016, the company's management team has experience in developing and commercializing innovative therapies. The company's strategy includes seeking regulatory approval and maximizing the U.S. commercial potential of TA-ERT for treating Mucopolysaccharidosis Type IIIB (MPS IIIB). They plan to seek U.S. accelerated approval for tralesinidase alfa enzyme replacement therapy ("TA-ERT") for MPS IIIB using existing non-clinical and clinical data. As a condition for a biologics license application ("BLA") from the U.S. Food and Drug Administration ("FDA"), a confirmatory trial will be initiated. If the BLA is approved, the company intends to build a specialized commercial and medical affairs organization to support TA-ERT's commercialization. TA-ERT has received Rare Pediatric Disease Designation, Fast Track Designation, Breakthrough Therapy Designation, and Orphan Drug Designation in the United States and European Union ("EU"). The company aims to commercialize TA-ERT and its other investigational products globally, including North America, the EU, the United Kingdom, Latin America, Turkey, Asia, and other international markets. They plan to establish their own commercial organization in the United States, EU, and the United Kingdom, and seek regional strategic collaborations and third-party distributors in other international markets. The company focuses on serious diseases with significant unmet medical need and clear, well-understood biology.

Spruce Biosciences, Inc. (NASDAQ:SPRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for SPRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for SPRB spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Spruce 10-Q: $24M Q3 Loss, $87.7M Cash, Going-Concern Warning Ahead of December BLA
  • Spruce Q3 Loss Widens to $24M; Avenue Loan Amended, Adrenyx Spin Terms Set
  • Spruce Biosciences Posts $24M Q3 Loss, Cash of $87.7M Ahead of December BLA Filing
  • Spruce Spins Out CRHX-101 Into Adrenyx, Targets Two Public Companies by H1 2027
  • FDA Endorses Spruce's BLA Plan for TA-ERT; Submission on Track for Q4

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$38.97M
Diluted EPS
-$50.83
Op. Cash Flow
-$33.33M
Operating Income
-$36.51M
Cash & Equivalents
$48.91M
Total Debt
$0
Debt / Equity
0.00×
Shares Outstanding
1.37M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-097558

Short Interest & Short Volume

6.95 days to cover

FINRA reported short interest of 531,380 shares in SPRB as of the October 30, 2026 settlement, a 1.8% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 56.9% of SPRB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)531,380 shares as of October 30, 2026
Change vs prior period▲ 1.8%
Days to cover6.95 at avg daily volume of 76,446
Daily short volume (FINRA facilities)56.9% of 42,521 shares on November 20, 2026
5-day average short volume64.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$38
52-week range · as of 2026-11-09 $38 – $129
Market cap
$109.21M
Volume
108.3K (1.4× avg)
3-mo avg 78.8K
Live data · 2026-11-22 12:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SPRB - Latest Insights

SPRB
Nov 09, 2026, 8:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $45.07
Real-time Price: $38.00 info
Change: -$7.07 (-16%) info
Market Cap: $109.212M info
SPRB
Nov 09, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $45.07
Real-time Price: $38.00 info
Change: -$7.07 (-16%) info
Market Cap: $109.212M info
SPRB
Nov 09, 2026, 8:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $46.55
Real-time Price: $38.00 info
Change: -$8.55 (-18%) info
Market Cap: $109.212M info
SPRB
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $46.55
Real-time Price: $38.00 info
Change: -$8.55 (-18%) info
Market Cap: $109.212M info
SPRB
Aug 24, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $51.58
Real-time Price: $38.00 info
Change: -$13.58 (-26%) info
Market Cap: $109.212M info
SPRB
Aug 12, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.41
Real-time Price: $38.00 info
Change: -$8.41 (-18%) info
Market Cap: $109.212M info
SPRB
Aug 12, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $46.41
Real-time Price: $38.00 info
Change: -$8.41 (-18%) info
Market Cap: $109.212M info
SPRB
May 13, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.55
Real-time Price: $38.00 info
Change: -$19.55 (-34%) info
Market Cap: $109.212M info
SPRB
May 13, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $56.67
Real-time Price: $38.00 info
Change: -$18.67 (-33%) info
Market Cap: $109.212M info
SPRB
May 13, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $56.67
Real-time Price: $38.00 info
Change: -$18.67 (-33%) info
Market Cap: $109.212M info
SPRB
Apr 22, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $54.00
Real-time Price: $38.00 info
Change: -$16.00 (-30%) info
Market Cap: $109.212M info
SPRB
Apr 21, 2026, 5:50 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $54.00
Real-time Price: $38.00 info
Change: -$16.00 (-30%) info
Market Cap: $109.212M info
SPRB
Apr 21, 2026, 5:23 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $54.00
Real-time Price: $38.00 info
Change: -$16.00 (-30%) info
Market Cap: $109.212M info
SPRB
Apr 20, 2026, 11:45 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $60.45
Real-time Price: $38.00 info
Change: -$22.45 (-37%) info
Market Cap: $109.212M info
SPRB
Apr 20, 2026, 4:02 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $65.01
Real-time Price: $38.00 info
Change: -$27.01 (-42%) info
Market Cap: $109.212M info
SPRB
Apr 09, 2026, 5:02 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $66.01
Real-time Price: $38.00 info
Change: -$28.01 (-42%) info
Market Cap: $109.212M info
SPRB
Mar 20, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $58.40
Real-time Price: $38.00 info
Change: -$20.40 (-35%) info
Market Cap: $109.212M info
SPRB
Mar 09, 2026, 7:31 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $56.04
Real-time Price: $38.00 info
Change: -$18.04 (-32%) info
Market Cap: $109.212M info
SPRB
Mar 09, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $56.04
Real-time Price: $38.00 info
Change: -$18.04 (-32%) info
Market Cap: $109.212M info
SPRB
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $56.04
Real-time Price: $38.00 info
Change: -$18.04 (-32%) info
Market Cap: $109.212M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets